The numbers emerging from Evvy’s five-year journey are beginning to tell a story, one that extends far beyond at-home vaginal health testing. With a dataset comprising 100,000 patient vaginal microbiomes, the company has quietly been building a foundation for something much larger. Now, a significant $40 million Series B funding round, led by Catalio Capital Management, signals a pivotal shift from consumer-facing services to a deeper dive into biotech research, leveraging this unique data trove.
Priyanka Jain, Evvy’s cofounder and CEO, emphasizes the growing body of third-party research highlighting the vaginal microbiome’s broad influence on women’s health. For Jain, the company’s accumulated data is not just a collection of samples, but a powerful tool poised to answer critical questions in this field. The immediate focus for this research initiative will be fertility, with projects already underway. One notable effort involves collaborating with IVF clinics, analyzing patient samples to identify novel markers of infection and inflammation that could predict the success or failure of implantation. Evvy has previously published studies validating its testing methodology and showcasing how its precision medicine approach can enhance patient outcomes. This new capital infusion is earmarked to validate ongoing studies and expand their research endeavors.
Raising this latest round was not without its complexities, as Jain and her cofounders discovered. While the women’s health sector has gained traction among early-stage investors, the landscape for growth-stage funding proved less mature. Jain likened the experience to fundraising in 2020, requiring substantial education for potential investors unfamiliar with the growth trajectory of companies in this category. Evvy finds itself among the pioneering firms graduating to this next stage, carving out a path for others to follow. 
A recurring challenge during the fundraising process was the pressure to specialize. Investors frequently urged Evvy to choose between its consumer brand identity and its burgeoning biotech aspirations. Consumer-focused investors, impressed by the brand’s appeal and loyal customer base, often questioned the extensive research efforts, suggesting a pivot towards, for instance, supplements. Conversely, biotech investors, captivated by the scale and potential of Evvy’s dataset, wondered why resources were being allocated to the consumer side. This dichotomy presented a strategic dilemma for the company’s leadership.
Despite these external pressures, Evvy plans to maintain its dual approach. The $40 million investment will not only fuel the expansion of its research capabilities but also enable the scaling of the Evvy consumer brand, particularly through increased presence in doctors’ offices. This integrated strategy underscores a belief that both facets are crucial to their overarching mission. The experience of educating growth investors about the nuances of women’s health, as Evvy has done, may well smooth the path for other companies in the sector as they mature and seek similar funding. The investment community, having received at least one intensive crash course in this evolving category, might now be better prepared for the next wave of innovation.
